Compare MTRX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTRX | RCKT |
|---|---|---|
| Founded | 1984 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.5M | 340.9M |
| IPO Year | 1990 | N/A |
| Metric | MTRX | RCKT |
|---|---|---|
| Price | $11.91 | $3.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 14 |
| Target Price | $17.00 | ★ $29.12 |
| AVG Volume (30 Days) | 225.6K | ★ 2.0M |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $815,591,000.00 | N/A |
| Revenue This Year | $20.43 | N/A |
| Revenue Next Year | $10.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.16 | N/A |
| 52 Week Low | $9.33 | $2.19 |
| 52 Week High | $16.11 | $13.35 |
| Indicator | MTRX | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 46.33 | 47.12 |
| Support Level | $11.68 | $3.30 |
| Resistance Level | $12.59 | $3.57 |
| Average True Range (ATR) | 0.42 | 0.19 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 49.44 | 28.95 |
Matrix Service Co provides engineering, fabrication, construction, maintenance, and repair services prominently to the energy and industrial markets. The company operates through three main segments: Storage and Terminal Solutions, Utility and Power Infrastructure, and Process and Industrial Facilities. These segments cover services like building and maintaining storage tanks and terminals, supporting power delivery and new power generation projects including renewables, as well as plant maintenance and turnarounds for refining and petrochemical industries. Matrix generates revenue by delivering these services to clients in oil, gas, power, and petrochemical sectors across North America and internationally.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.